08:36 AM EDT, 10/16/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) said Thursday that data from the ongoing Tuscany trial of tuspetinib in combination with anti-cancer therapies venetoclax and azacitidine (TUS+VEN+AZA) are being presented in a poster presentation at a conference this week in Portugal.

Data from 10 patients in the Tuscany trial across all three cohorts (40 mg, 80 mg or 120 mg tuspetinib dose), reveal "promising" clinical safety and antileukemic activity and support the use of the drug with standard of care treatment across a broad range of acute myeloid leukemia (AML) populations, including those carrying adverse mutations, a statement said.

Dosing has begun at the 160 mg tuspetinib dose level, the company added.

"We have observed that TUS can be safely added to a backbone VEN+AZA without needing to reduce the dose of these standard-of-care drugs. The activity we have observed with the TUS triplet in the first 10 patients has exceeded our expectations with 9 achieving complete remissions and 7 demonstrating MRD-negativity by central flow cytometry," said Rafael Bejar, chief medical officer.

"In addition, these remissions are happening in diverse genetic subtypes, . . . making this a truly mutation agnostic therapy."